ported in nonchordate animal phyla even though the CYPJ9 family appears to be an ancient lineage of P450 gene products, diverging as much as iO years ago (5). In most vertebrate species that have been examined, aromatase expression occurs in the gonads and in the brain. This is true of the fish and avian species that have been examined as well as most mammals, such as rodents. In many species, estrogen biosynthesis in the brain has been implicated in sex-related behavior such as mating responses, and frequently a marked sexually dimorphic difference has been demonstrated. This is true, for example, in avian species in which the song of the male is important in courtship behavior (11). In the case of humans and a number of higher primates, there is a more extensive tissue distribution of estrogen biosynthesis, since this also occurs in the placenta of the developing fetus as well as in the adipose tissue of the adult. The ability of the placenta to synthesize estrogen is also the property of numerous ungulate species such as cows, pigs, and horses. However, at least in cattle there is no evidence of estrogen biosynthetic capacity in adipose, whereas in rodents such as rat and mice, as well as rabbits, neither adipose nor placenta has any ability to synthesize estrogens. (13, 14) , and has been correlated directly with the incidence of endometrial cancer as well as with postmenopausal breast cancer. Furthermore, evidence is accumulating to suggest that the estrogen implicated in the development of breast cancer is that which is produced locally within the adipose tissue of the breast itself (15). On the other hand, estrogen biosynthesis in adipose tissue may have beneficial consequences because osteoporosis is more common in small, thin women than in large, obese women. Although this may be, in part, the consequence of the bones of the latter being subject to load-bearing exercise, nonetheless it seems likely that the increased production of estrogens by the adipose tissue of obese women is a significant factor.
THE CYPJ9 GENE
Some years ago we and others cloned and characterized the CYPJ9 gene, which encodes human P4SOarom (16) (17) (18) ( Fig. 1) . The coding region spans nine exons beginning with exon II. Sequencing of RACE-generated cDNA clones derived from P4SOarom transcripts present in the various tissue sites of expression revealed that the 5'-termini of these transcripts differ from one another in a tissue-specific fashion upstream of a common site in the 5'-untranslated region (19) (20) (21) (22) . Using these sequences as probes to screen genomic libraries, it was found that these 5'-termini correspond to untranslated exons which are spliced into the P4SOarom transcripts in a tissue-specific fashion, due to the use of tissue-specific promoters. Placental transcripts contain at their 5'-ends untranslated exon 1.1, which is located at least 40 kb upstream from the start of translation in exon 11 (19, 23) . This is because placental expression is driven from a powerful distal placental promoter, Fig. 2) and have found it to contain a TATAless promoter, as well as an upstream GRE and an Spi sequence within the untranslated exon, both of which are required for expression of reporter gene constructs in the presence of serum and glucocorticoids (32). We also found this region to contain a GAS (interferon-y activating sequence) element. Such sequences are known to bind transcription factors of the STAT family (33-35).
We have studied aromatase expression in samples of adipose tissue obtained from women of various ages, using RT-PCR with an internal standard, and have found a marked increase in the specific content of P4SOarom transcripts in adipose tissue with increasing age, thus providing a molecular basis for the previous observation that the fractional conversion of circulating androstenedione to estrone increases with age (36). Furthermore, there are marked regional variations in aromatase expression, with highest values being found in adipose tissue from the buttocks and thighs compared to that from abdomen and breast (31, 36).
We also used this RT-PCR technique to examine regional variations in aromatase expression in breast adipose tissue and have found that the highest expression occurs in adipose tissue proximal to a tumor, as compared to that distal to a tumor (37, 38 
CYTOKINES THAT STIMULATE AROMATASE EXPRESSION IN ADIPOSE TISSUE
Recently, we observed for the first time that the effect of serum to stimulate aromatase expression in human adipose stromal cells (in the presence of glucocorticoids) can be mimicked by specific factors: members of the interleukin-11 (IL-l 1),2 oncostatin-M (OSM), and leukemia inhibitory factor (LIF) cytokine families (43, 44). Ligands that have no effect include interferon-a and interferon-'y; IL-6, which is also a member of the IL-li and OSM cytokine family, was of itself ineffective.
However, responsiveness to IL-6 was established upon addition of soluble IL-6 receptor. Members of this cytokine family use a receptor system involving two different Jak-associated components, gpl3O and LIFR or a related 13-component (45 dicate that both deletion of the GAS sequence, as well as mutagenesis of this sequence, resulted in complete loss of IL-iland serum-stimulated expression in the presence of glucocorlicoids.
Activation of this pathway of expression by these cytokines is absolutely dependent on the presence of glucocorticoids.
This action of glucocorticoids is mediated by a GRE element downstream of the GAS element (32). In addition, an Spi-like element present within untranslated exon 1.4 also is required, at least for expression of the -330/+i70bp construct (32). These sequences, although present within a 400 bp region of the gene, are not contiguous, and the nature of the interaction between STAT3, the glucocorticoid receptor, and Spi to regulate expression of the P4SOarom gene via the distal promoter 1.4 remains to be determined.
Our present understanding of the regulation of expression of aromatase in adipose tissue is summarized in Fig. 3 .
Activation of aromatase expression
by serum in the presence of glucocorticoids is not confined to cells present in adipose tissue, but has also been reported in skin fibroblasts (52) and in hepatocytes derived from fetal liver (53). In each of these cell types, the P4SOarom transcripts contain exon 1.4 as their 5'-terminus (26, 54); however, the factors that mimic the action of serum to stimulate aromatase expression in these cell types have as yet to be elucidated.
On the other hand, in placenta where the distal promoter 1.1 is used (19) and in ovarian granulosa cells where the proximal promoter II is used (19, 22) , this signaling pathway is not in effect. Thus, aromatase expression in ovarian granulosa cells is driven primarily by cyclic AMP-dependent mechanisms (55).
MESENCHYMAL-EPITHELIAL INTERACTIONS IN REGULATION OF AROMATASE EXPRESSION IN ADIPOSE TISSUE
As indicated previously, adipose tissue is the major site of estrogen biosynthesis in elderly women and men. That this expression is confined to the stromal cells rather than the adipocytes themselves is consistent with the known actions of IL-li to inhibit the differentiation of 3T3 Ll fibroblasts into adipocytes (56). Because adipose stromal cells are believed to function as preadipocytes and can be converted to adipocytes under appropriate nutritional stimuli, a role for these cytokines may be to maintain these cells in the preadipocyte state for which aromatase expression is a marker. As indicated previously, aromatase expression in adipose increases dramatically with age (36, 57). There is also a marked regional distribution, with expression being greatest in buttock and thigh regions as compared to abdomen and breast (36, 58) . However, within the breast there is also a marked regional variation, with expression being highest in sites proximal to a tumor as compared to those distal to a tumor (37, 38). Based on the results presented here, we suggest that aromatase expression in adipose tissue may be under tonic control by circulating glucocorticoids and that regional and age-dependent variations may be the consequence of paracrine and autocrine secretion of cytokines. Schmidt and Loffler (59), as well as ourselves (60) is also expressed to a very high level in the brain (7-9). Recently, it has been shown that, in the goldfish, two transcripts for aromatase exist, one in an ovary and one in the brain, which differ significantly throughout the entire coding region, indicative of the presence of two separate genes (66). Thus, the issue of the evolution of the human gene with a single coding region, but with multiple untranslated first exons, becomes an interesting and complex issue. Another variant on this theme occurs in the pig (67) in which placental transcripts differ from those in the ovary at several regions in the coding region. This is consistent with one gene with alternatively spliced coding exons. Thus, the phylogenetic evolution of the aromatase gene will likely turn out to be very complex.
It is clear that, in most vertebrates, aromatase expression is confined to the brain and the gonads. However, as indicated previously in a number of mammals, including primates and some ungulate species such as the cow, pig, and horse, expression also occurs in the placenta. In all of these species it appears that a unique placental-specific distal promoter is used. Since SF-i is apparently not expressed in placenta, this may explain why the proximal promoter of aromatase is not used in this fetal tissue; rather, a distal promoter is used that is regulated by mechanisms totally independent from those involving SF-i. Thus, whereas SF1 may play a critical role in both the 
